Helospectin from Heloderma Venom: A VIP‐Like Vasodilatory Peptide for Erectile Dysfunction and Clitoral Engorgement—A Theoretical Preclinical Proposal

Background: Erectile dysfunction (ED) affects approximately 52% of men aged 40–70 years in population-based cohorts and is strongly associated with vascular and metabolic disease, particularly diabetes mellitus.[1] In Saudi Arabia, diabetes prevalence in adults is estimated at over 20%, magnifying the burden of vasculogenic ED.[2] Phosphodiesterase-5 inhibitors (PDE5i) improve erectile function but have limitations in patients with endothelial dysfunction, neurogenic compromise, or contraindications to nitrates.[3]Hypothesis: Helospectins I and II are 37–38–amino-acid peptides isolated from Heloderma (Gila monster and Mexican beaded lizard) venom that belong to the glucagon/VIP superfamily and exhibit potent vasodilatory, smooth muscle–relaxant, and hypotensive effects.[4,5] Building on the successful translation of the venom peptide exendin-4 into the antidiabetic drug exenatide,[6,7] we hypothesize that synthetic helospectin analogues could serve as selective agonists at VPAC1/VPAC2 receptors in genital vascular smooth muscle, promoting corpus cavernosum and clitoral vasodilation independent of endothelial nitric oxide (NO), and thereby treating ED and clitoral engorgement (female sexual arousal disorder, FSAD).[8–10]Methods (theoretical proposal): We outline (i) a biochemical and physiological rationale based on helospectin/VIP homology, distribution of VIP-family peptides in male and female genital tissues, and venom-derived pharmacology; (ii) a conceptual mechanism of action centred on cAMP/PKA-mediated relaxation of cavernosal and clitoral smooth muscle; and (iii) a Phase I/IIa randomized, double-blind, placebo-controlled crossover trial of intranasal synthetic helospectin in men with ED and women with FSAD.Expected outcomes: We anticipate that helospectin analogues could augment genital blood flow and erection/engorgement responses in a manner that is at least partly independent of endothelial NO, potentially benefiting patients with diabetic and neurogenic ED. Safety concerns include systemic hypotension, off-target vasodilation, and theoretical effects on exocrine pancreas and gut. This preprint is offered as a hypothesis-generating framework to encourage collaborative medicinal chemistry and preclinical work, not as evidence for clinical use